Wall Street Zen Downgrades AC Immune (NASDAQ:ACIU) to Sell

AC Immune (NASDAQ:ACIU) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts also recently issued reports on ACIU. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AC Immune has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Stock Performance

ACIU stock opened at $3.19 on Friday. The stock has a market capitalization of $320.31 million, a PE ratio of -3.80 and a beta of 1.66. The company has a fifty day moving average of $3.21 and a 200-day moving average of $2.88. AC Immune has a one year low of $1.43 and a one year high of $4.00.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $0.81 million. AC Immune had a negative net margin of 1,642.89% and a negative return on equity of 84.32%. Equities analysts forecast that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ACIU. Private Advisor Group LLC acquired a new stake in AC Immune in the 3rd quarter valued at about $48,000. Susquehanna International Group LLP acquired a new position in AC Immune during the third quarter worth about $63,000. Sei Investments Co. purchased a new stake in shares of AC Immune in the second quarter valued at about $51,000. Acadian Asset Management LLC grew its position in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of AC Immune in the third quarter valued at approximately $549,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.